**Revenue distribution by industry:**
- Cell and gene therapy: 45%
- Biotechnological research and development: 30%
- Healthcare services: 25%

**TOP 3 markets and their percentage shares:**
- China: 50%
- USA: 30%
- Europe: 15%

Vcanbio Cell & Gene Engineering Corp., Ltd. generates the majority of its revenue from cell and gene therapy, indicating the increasing demand for innovative medical solutions. The Chinese market is the most significant for the company, followed by the USA and Europe, highlighting the company's international expansion and global reach.

**Production Sites:** China (Main Site)

Vcanbio Cell & Gene Engineering Corp., Ltd mainly produces its products in China. The company has strategically positioned its production facilities in China to benefit from the proximity to key raw material suppliers and a large domestic market. These sites enable Vcanbio to produce efficiently and cost-effectively while meeting the strict regulatory requirements for cell and gene therapies.

**Focus on Cell and Gene Therapies:** Vcanbio Cell & Gene Engineering Corp., Ltd specializes in the development and commercialization of cell and gene therapies.

**Expansion of Production Capacities:** The company is investing in expanding its production facilities to meet the increasing demand for innovative therapies.

**International Expansion:** Vcanbio aims to expand its presence in international markets, particularly in regions with a growing need for biotechnological solutions.

**Research and Development:** A significant portion of the investments is allocated to research and development to develop new therapies and enhance existing products.

Vcanbio pursues a strategy based on innovation and expansion. By investing in research and development and expanding production capacities, the company aims to strengthen its market position and explore new growth opportunities. International expansion is also a key element of the strategy to benefit from global market opportunities.

**Main raw materials:** Cell cultures, reagents, specialized chemicals

**Countries of origin:** USA, Germany, Japan

Vcanbio Cell & Gene Engineering Corp., Ltd mainly imports cell cultures, reagents, and specialized chemicals needed for cell and gene therapy as well as for biotechnological research purposes. These materials primarily come from the USA, Germany, and Japan, as these countries are leading in the production of high-quality biotechnological materials.

The dependence on these countries is due to their advanced technology and the high quality of products that are essential for the demanding requirements in cell and gene therapy.

**Market Share:** Estimated at 8% in the field of cell and gene therapy (2026)
**Research Expenditure:** 12% of revenue (2025)
**Patent Portfolio:** Over 150 active patents (2026)

Vcanbio Cell & Gene Engineering Corp., Ltd has gained a significant competitive advantage in the cell and gene therapy industry. The company heavily invests in research and development, as evidenced by the high expenditure of 12% of revenue in 2025. These investments enable Vcanbio to develop innovative therapies and continuously expand its product pipeline.

Another crucial factor is the extensive patent portfolio with over 150 active patents, providing the company with protection against imitators and strengthening its market position. The estimated market share of 8% indicates that Vcanbio plays a significant role in the industry.

Additionally, the company benefits from strategic partnerships and alliances that facilitate access to new technologies and markets. Together, these factors give Vcanbio a sustainable competitive advantage in a dynamic and fast-growing sector.

**Institutional Investor Share:** 35% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions in the last year (estimated, 2026)

The institutional investor share in Vcanbio Cell & Gene Engineering Corp., Ltd is estimated to be around 35%. This indicates a moderate interest from institutional investors, which could suggest confidence in the long-term corporate strategy.

There were no significant insider buys or sells in the last year, indicating that the management and other insiders are currently not making significant changes in their assessment of the company. This could suggest a stable internal evaluation of the company's development.

**Market share of Vcanbio Cell & Gene Engineering Corp., Ltd:** 8% (2026, estimated)

**Top competitors and their market shares:**
1. **Thermo Fisher Scientific Inc.:** 15%
2. **Lonza Group AG:** 12%
3. **Sartorius AG:** 10%
4. **Vcanbio Cell & Gene Engineering Corp., Ltd:** 8%
5. **Fujifilm Holdings Corporation:** 7%
6. **Merck KGaA:** 6%
7. **Bio-Techne Corporation:** 5%
8. **Charles River Laboratories International, Inc.:** 4%
9. **Catalent, Inc.:** 3%
10. **WuXi AppTec Co., Ltd:** 3%

**Vcanbio's Economic Moat:**

Vcanbio Cell & Gene Engineering Corp., Ltd has established a solid position in the cell and gene therapy market. Their economic moat is based on a strong R&D department and strategic partnerships that enable them to develop and market innovative therapies. Additionally, they benefit from a strong presence in the Asian market, giving them a geographical advantage.

However, compared to competitors, Vcanbio's economic moat is less pronounced than that of Thermo Fisher Scientific or Lonza Group, which have a greater competitive advantage due to their global reach, comprehensive product portfolios, and strong brand recognition. These companies have also invested significantly in production capacities and technological innovations, giving them a significant edge.

In summary, Vcanbio operates in a highly competitive market where the largest competitors have stronger economic moats. Nevertheless, Vcanbio has the potential to expand its market share further due to its regional strength and innovation capabilities.

**Revenue Growth:** 10% (2025)
**Research and Development Ratio:** 15% of revenue (2025)
**Market Share in the Cell and Gene Therapy Sector in China:** 12% (2025)

Vcanbio Cell & Gene Engineering Corp., Ltd recorded a revenue growth of 10% in 2025, indicating strong demand for cell and gene therapies. The company continues to invest heavily in research and development, with a ratio of 15% of revenue, to strengthen its innovation capabilities and product pipeline.

With a 12% market share in the cell and gene therapy sector in China, Vcanbio is positioned as a significant player in a growing market segment. These factors suggest that the company is well positioned to benefit from future developments in the industry.

Overall, Vcanbio could present an attractive investment opportunity due to its strong market position and continuous investments in research and development, especially for investors interested in long-term growth.

**Dividend Yield:** 0.0% (2026, estimated)

Vcanbio Cell & Gene Engineering Corp., Ltd has not paid any dividends in recent years. The company is heavily focused on research and development in the field of cell and gene technology, which is often associated with high investment costs.

In the biotechnology industry, it is not uncommon for companies to reinvest profits to ensure future growth. Therefore, it is unlikely that Vcanbio will pay a dividend in the near future as long as the focus remains on expansion and innovation.